199850-56-1

Basic information

• Product Name: BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER
• Synonyms: BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER;Methyl 2-aMino-4-chloro-5-iodobenzoate;Methyl 4-chloro-5-iodoanthranilate;2-AMino-4-chloro-5-iodo-benzoic acid Methyl ester
• CAS NO: 199850-56-1
• Molecular Formula: C₈H₇ClINO₂
• Molecular Weight: 311.501
• Mol File: 199850-56-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 369.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.903
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.99±0.10(Predicted)
• CAS DataBase Reference: BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER(199850-56-1)
• EPA Substance Registry System: BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER(199850-56-1)

Safety Data

• Hazardous Substances Data: 199850-56-1(Hazardous Substances Data)

Usage

General Description

BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER is a chemical compound that consists of a benzoic acid core with amino, chloro, and iodo substituents attached. It is also known as 4-Chloro-5-iodo-2-aminobenzoic acid methyl ester and is often used in organic synthesis and pharmaceutical research as an intermediate or building block for the synthesis of various pharmaceutical compounds. BENZOIC ACID, 2-AMINO-4-CHLORO-5-IODO-, METHYL ESTER has potential applications in the development of new drugs and medical treatments, and its properties and reactivity make it an important chemical for medicinal chemistry and pharmaceutical research.

Upstream product

• 147778-06-1 2-acetylamino-4-chlorobenzoic acid methyl ester 
• 717879-44-2 methyl 2-amino-4-tert-butylbenzoate 
• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 

Downstream Products

• 540501-04-0 2-amino-4-chloro-5-iodobenzoic acid 

Relevant articles and documents

A targeted delivery strategy for the development of potent trypanocides

A new drug delivery strategy was investigated for the development of potent anti-parasitic compounds against Trypanosoma brucei, the causative agent of African sleeping sickness. Thus, potent in vitro hexokinase inhibitors were rendered cytotoxic by appending a tripeptide peroxosomal targeting sequence that facilitated delivery of the molecular cargo to the appropriate organelle in the parasite.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.